Unternehmensübersicht
Reviva Pharmaceuticals Holdings, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry where it discovers, develops, and commercializes next-generation therapeutics aimed at addressing unmet medical needs in central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's current scale is defined by a market capitalization of $10.12 million and an employed workforce consisting of 14 individuals. While specific annual revenue data is not disclosed in the available financial records, the company's market capitalization indicates a small-cap status, reflecting the early-stage nature of its therapeutic development pipeline. This valuation suggests that the market prices the company based on the potential future value of its product candidates rather than current cash flow generation from commercialized assets.
Finanzielle Gesundheit
The financial performance of Reviva Pharmaceuticals Holdings, Inc. is characterized by a net income of -$19,864,900 over the trailing twelve months and an EBITDA figure that is not available for reporting, alongside revenue that is currently unquantified in the provided data. The significant negative net income relative to the lack of reported revenue highlights a cost structure dominated by research and development expenditures typical of biotechnology firms in the pre-revenue or early commercialization phase. The company reported a free cash flow of -$17,137,860, which indicates a consumption of cash reserves to fund its operational activities and scientific investigations. Despite this cash burn, the balance sheet retains $14.44 million in cash and cash equivalents, providing a buffer against ongoing operational expenses. However, the company carries $406,875 in debt, resulting in a debt-to-equity ratio of 4.71, which suggests a leveraged capital structure relative to its equity base. The current ratio stands at 2.08, indicating that the company holds sufficient current assets to cover its short-term liabilities with a margin of safety. Return on Equity is recorded at -420.0% and Return on Assets at -80.3%, metrics that reflect the dilution of shareholder value and asset efficiency during periods of negative earnings and high operational costs.
Bewertungsanalyse
Valuation multiples for Reviva Pharmaceuticals Holdings, Inc. present a mixed picture, with the trailing twelve-month P/E ratio listed as not available and a forward P/E of -0.96. The negative forward P/E ratio implies that the market expects earnings to remain negative in the near term, a common characteristic for biotechnology companies that have not yet achieved consistent profitability. The price-to-book ratio is calculated at 0.54, suggesting that the market values the company at significantly less than its net asset value, which often occurs when intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available, limiting the ability to perform traditional comparative valuations against peers with established sales streams. The stock's price volatility is evident from its 52-week trading range, which fluctuated between a high of $23.20 and a low of $0.59. Given the 52-week low of $0.59 and the high of $23.20, the current trading price sits within a wide range that reflects high uncertainty and potential for significant price swings. The beta coefficient is recorded at 0.64, indicating that the stock's price movements are less volatile than the broader market index.
Growth & Income
The company's growth trajectory is constrained by the absence of reported revenue growth year-over-year and earnings growth year-over-year, as these metrics are not available in the current financial dataset. Without positive earnings, the company does not distribute dividends to shareholders, evidenced by a dividend yield of not available and a payout ratio of 0.0%. Consequently, Reviva Pharmaceuticals Holdings, Inc. must reinvest its remaining cash reserves entirely into its R&D pipeline and operational expansion rather than returning capital to investors. The overall growth and income profile for Reviva Pharmaceuticals Holdings, Inc. is currently defined by capital appreciation potential driven by clinical trial outcomes and regulatory approvals rather than income generation or dividend payments.